The CDMO’s GMP plant will dedicate 2,500 square feet to the storage of finished products.
SOHM, Inc., a pharmaceutical, nutraceutical, and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, is introducing its new manufacturing facility in Carlsbad, CA.1
In order to meet the rising demand for its products, the facility will handle the orders that SOHM has received and expects to receive in the near future, while its main facility in downtown San Diego undergoes renovation to become fully operational. SOHM aims to complete the engineering batches produced in the San Diego facility by Q1 of next year. This expansion is part of the company’s strategic plan to enhance its production capacity and efficiency.
This new Carlsbad facility is expected to feature enough space for the contract development and manufacturing organization (CDMO) to manufacture topical products and SOHM’s operations, including 2,500 square feet allocated to storage of finished products. It will have an initial daily capacity of 500 gallons (1,892 liters) with initial manufactured products of topicals but will be expected to add soft-gel suppositories to its capacity by end of Q1 2024 /beginning of Q2 2024.
As of press time, the facility is near-final. Full current good manufacturing practice (cGMP) manufacturing capacity is expected to be completed by December 2023.
This announcement comes at a time when as of this year, the bio and pharma CDMO market is $223 billion and is expected to grow to $309 billion by 2028, implying a 6.74% compound annual growth rate (CAGR) between 2018 and 2028. The largest CDMO market is North America, with the largest production market being Asia, according to Mordor Intelligence.2 Overall, the study notes, the US, China, India, and Germany represent the largest country markets for CDMOs; the US specifically is in the top three, but is lagging behind India, Germany, and South Africa when it comes to future growth.
“I am very proud to launch this facility with our SOHM team members. This Carlsbad facility is conveniently located right at the mid-way between two importing commercial hubs: Los Angeles and San Diego. Our location on major land shipping routes will play an important role in maintaining our competitive pricing edge in material sourcing and final products to our clients. Many people do not know this, but Carlsbad is also the home to many biotech and pharma companies who routinely rely on CDMO operators like SOHM for their bio-manufacturing needs,” says David Aguilar, PhD, SOHM’s COO.
He continues, “In 12 months, our Carlsbad facility will be expecting to manufacture 70% Rx and 30% OTC (over-the-counter) products. This facility will be able to meet all of our short-term SOHM brand Rx topical and OTC product manufacturing with 100% allocated to manufacture for CDMO clients whose orders are now arriving for year-end-2023.”
1. SOHM Announces New CDMO GMP Manufacturing Facility in Carlsbad, California. GlobeNewswire. November 21, 2023. Accessed November 22, 2023. https://www.globenewswire.com/news-release/2023/11/21/2784138/0/en/SOHM-Announces-New-CDMO-GMP-Manufacturing-Facility-in-Carlsbad-California.html
2. CDMO Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028). Mordor Intelligence. Accessed November 22, 2023. https://www.mordorintelligence.com/industry-reports/pharmaceutical-contract-development-and-manufacturing-organization-cdmo-market